{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:49:22Z","timestamp":1782452962336,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To comprehensively evaluate the real-world post-marketing safety profile of the novel dissociative steroid Vamorolone and perform a comparative analysis against the traditional glucocorticoid deflazacort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Vamorolone-associated adverse event reports were extracted from the FAERS database (2023Q4\u20132025Q4) without indication restrictions to maximize detection sensitivity. Disproportionality analysis utilized ROR, PRR, BCPNN, and MGPS, reinforced by a strict Bonferroni correction to assess statistical robustness against multiple testing. Signal novelty was systematically assessed against the official FDA prescribing information. Temporal onset was evaluated via the Weibull distribution. To rigorously compare safety profiles across skeletal, growth, endocrine, and psychiatric domains, an exploratory head-to-head analysis was conducted using 2 \u00d7 2 contingency tables to calculate crude odds ratios against deflazacort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 1,171 cases (97.0% explicitly confirmed for muscular dystrophy) comprising 2,860 reported adverse events. Multi-algorithm consensus screening yielded a final refined cohort of 60 potential adverse event signals, predominantly concentrated within psychiatric disorders, investigations, and infections. Label cross-referencing revealed known risks (e.g., stubbornness, EBGM = 163.78 and acute adrenocortical insufficiency, EBGM = 71.14) and potentially novel signals (e.g., enuresis, EBGM = 42.40 and troponin I increased, EBGM = 39.54) that maintained statistical robustness under the stringent Bonferroni threshold. AEs exhibited an \u201cearly failure\u201d onset (\u03b2 = 0.74), particularly rapid for psychiatric events (median 36.5 days, \u03b2 = 0.57). Comparatively, Vamorolone showed significantly lower reporting odds than deflazacort for growth retardation (Crude OR = 0.15, P = 0.003), osteoporosis (Crude OR = 0.27, P = 0.02), and femur fracture (Crude OR = 0.38, P = 0.008), while psychiatric signals remained comparable (P &amp;gt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Exploratory analyses generate the hypothesis that Vamorolone may be associated with lower reporting odds for skeletal and growth-related adverse events compared to deflazacort. Nevertheless, known risks and unexpected hypothesis-generating signals\u2014such as notable HPA axis suppression and early-onset psychiatric disturbances\u2014remain critical safety concerns. Clinicians should interpret these differential reporting patterns with caution and rigorously monitor neurobehavioral and adrenal health during the first three months, with further external validation warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1838974","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:23Z","timestamp":1782452663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety surveillance and signal characterization of the novel dissociative steroid Vamorolone in Duchenne muscular dystrophy: a comparative disproportionality analysis based on FAERS data"],"prefix":"10.3389","volume":"17","author":[{"given":"Yining","family":"Zeng","sequence":"first","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Wang","sequence":"additional","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Tan","sequence":"additional","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Wang","sequence":"additional","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Eye School of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Duan","sequence":"additional","affiliation":[{"name":"Ineye Hospital of Chengdu University of TCM","place":["Chengdu, Sichuan, China"]},{"name":"Eye Health with Traditional Chinese Medicine Key Laboratory of Sichuan Province","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/clinem\/dgae521","article-title":"Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial","volume":"110","author":"Ahmet","year":"2025","journal-title":"J. Clinical Endocrinology Metabolism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. Journal Clinical Pharmacology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/wnl.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the cinrg duchenne natural history study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"B4","volume-title":"Agamree (Vamorolone) Oral Suspension Prescribing Information","author":"Catalyst Pharmaceuticals","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1093\/rheumatology\/keaf129","article-title":"Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects","volume":"64","author":"Crastin","year":"2025","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet Journal Rare Diseases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","article-title":"Evolving therapeutic options for the treatment of Duchenne muscular dystrophy","volume":"20","author":"D'Ambrosio","year":"2023","journal-title":"Neurother. The Journal Am. Soc. Exp. Neurother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e208112","DOI":"10.1212\/wnl.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109689","DOI":"10.1016\/j.steroids.2025.109689","article-title":"Mineralocorticoid receptor antagonism of vamorolone: evidence from lionheart and vision-dmd clinical trials","volume":"223","author":"de Vera","year":"2025","journal-title":"Steroids"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of Duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr. Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the Fda spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"B12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (Prrs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","article-title":"11\u03b2-Hsd1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Research and Therapy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and becker muscular dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol. Clinics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/10253890.2018.1470238","article-title":"Role of glucocorticoid negative feedback in the regulation of Hpa axis pulsatility","volume":"21","author":"Gjerstad","year":"2018","journal-title":"Stress Amsterdam, Neth."},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mus.23831","article-title":"Corticosteroids in Duchenne muscular dystrophy: major variations in practice","volume":"48","author":"Griggs","year":"2013","journal-title":"Muscle and Nerve"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/wnl.0000000000003217","article-title":"Efficacy and safety of deflazacort Vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3233\/jnd-230161","article-title":"Considering the promise of vamorolone for treating Duchenne muscular dystrophy","volume":"10","author":"Grounds","year":"2023","journal-title":"J. Neuromuscular Diseases"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone Vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu. Review Genomics Human Genetics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacology Therapeutics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","volume":"2","author":"Heier","year":"2019","journal-title":"Life Science Alliance"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134596","article-title":"Anti-inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy: exploration of steroid-sparing agents","volume":"21","author":"Herbelet","year":"2020","journal-title":"Int. Journal Molecular Sciences"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","article-title":"Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes","volume":"134","author":"Hoffman","year":"2018","journal-title":"Steroids"},{"key":"B26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pnpbp.2009.10.018","article-title":"Prednisolone causes Anxiety- and depression-like behaviors and altered expression of apoptotic genes in mice hippocampus","volume":"34","author":"Kajiyama","year":"2010","journal-title":"Prog. Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1677\/joe.0.1750251","article-title":"The role of the efflux transporter P-Glycoprotein in brain penetration of prednisolone","volume":"175","author":"Karssen","year":"2002","journal-title":"J. Endocrinology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jnnp.2007.141721","article-title":"Disability and survival in Duchenne muscular dystrophy","volume":"80","author":"Kohler","year":"2009","journal-title":"J. Neurology, Neurosurgery, Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"24285","DOI":"10.1073\/pnas.2006890117","article-title":"Disruption of a key Ligand-H-Bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddad173","article-title":"Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in dmd disease models","volume":"33","author":"Liu","year":"2024","journal-title":"Hum. Molecular Genetics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-Month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Network Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40199-025-00565-y","article-title":"Glucocorticoid withdrawal syndrome: disproportionality analysis of cases using vigibase data","volume":"33","author":"Mangal","year":"2025","journal-title":"Daru Journal Fac. Pharm. Tehran Univ. Med. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet London, Engl."},{"key":"B34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"Fda adverse event reporting system (faers) essentials: a guide to understanding, applying, and interpreting adverse event data reported to faers","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacology Therapeutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"Vbp15: preclinical characterization of a novel anti-inflammatory Delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg. and Medicinal Chemistry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of duchenne and becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Translational Medicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","article-title":"Global prevalence of duchenne and becker muscular dystrophy: a systematic review and meta-analysis","volume":"17","author":"Salari","year":"2022","journal-title":"J. Orthopaedic Surgery Research"},{"key":"B39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the us fda's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Safety"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinology Metabolism TEM"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejphar.2007.12.005","article-title":"A mouse model of depression induced by repeated corticosterone injections","volume":"581","author":"Zhao","year":"2008","journal-title":"Eur. Journal Pharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1838974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:25Z","timestamp":1782452665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1838974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1838974"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1838974","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1838974"}}